https://www.sec.gov/Archives/edgar/data/1636050/00010474691900119...

https://www.sec.gov/Archives/edgar/data/1636050/000104746919001193/a2238033z424b5.htm

The AXO-AAV-OPMD clinical program is expected to begin in the second half of 2019, and the final design will be informed by discussions with the FDA andother regulators.

from the Axovant prospectus:

	Gene Therapy Program		Clinical Indication		Development Stage
1	AXO-AAV-GM1		GM1 gangliosidosis		Clinical-ready
2	AXO-AAV-GM2		GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease)		Clinical
3	AXO-LENTI-PD		Parkinson's disease		Clinical
4	AXO-AAV-OPMD		Oculopharyngeal muscular dystrophy		Preclinical
5	AXO-AAV-ALS		Amyotrophic lateral sclerosis		Research
6	AXO-AAV-FTD		Frontotemporal dementia		Research
7	Four additional AXO-AAV		Undisclosed		Research
8	Collaboration Programs